YMTX Key Statistics, Chart & Performance
The current stock price of YMTX is 1.89 USD. In the past month the price increased by 5.59%. In the past year, price decreased by -43.24%.
YMTX Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to YMTX. When comparing the yearly performance of all stocks, YMTX is a bad performer in the overall market: 64.5% of all stocks are doing better.
YMTX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to YMTX. YMTX may be in some trouble as it scores bad on both profitability and health.
YMTX Financial Highlights
Over the last trailing twelve months YMTX reported a non-GAAP Earnings per Share(EPS) of -2.64. The EPS decreased by -337.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
YMTX Forecast & Estimates
9 analysts have analysed YMTX and the average price target is 35.7 USD. This implies a price increase of 1788.89% is expected in the next year compared to the current price of 1.89.
For the next year, analysts expect an EPS growth of -60.56% and a revenue growth 9.96% for YMTX
YMTX Ownership
About YMTX
Company Profile
Yumanity Therapeutics, Inc. is a clinical stage biopharmaceuticals company. The company is headquartered in Boston, Massachusetts and currently employs 40 full-time employees. The company went IPO on 2016-02-11. The firm is focused on the discovery and development of disease-modifying therapies for neurodegenerative diseases. The Company’s pipeline consists of programs focused on Parkinson’s disease, Lewy body dementia, multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), frontotemporal lobar dementia (FTLD), and Alzheimer’s disease. The firm's technology platform enables the rapid screening for disease targets and disease modifying drugs that can overcome toxicity in disease-causing gene networks, which results from an aberrant accumulation of misfolded proteins in the brain. The firm's product candidate includes YTX-7739, which is in Phase I clinical trials for the treatment and disease modification of Parkinson's disease.
Company Info
YUMANITY THERAPEUTICS INC
40 Guest Street, Suite 4410
Boston MASSACHUSETTS 02135 US
CEO: Richard Peters
Employees: 40
Phone: 16174095300.0
YUMANITY THERAPEUTICS INC / YMTX FAQ
What does YMTX do?
Yumanity Therapeutics, Inc. is a clinical stage biopharmaceuticals company. The company is headquartered in Boston, Massachusetts and currently employs 40 full-time employees. The company went IPO on 2016-02-11. The firm is focused on the discovery and development of disease-modifying therapies for neurodegenerative diseases. The Company’s pipeline consists of programs focused on Parkinson’s disease, Lewy body dementia, multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), frontotemporal lobar dementia (FTLD), and Alzheimer’s disease. The firm's technology platform enables the rapid screening for disease targets and disease modifying drugs that can overcome toxicity in disease-causing gene networks, which results from an aberrant accumulation of misfolded proteins in the brain. The firm's product candidate includes YTX-7739, which is in Phase I clinical trials for the treatment and disease modification of Parkinson's disease.
What is the current price of YMTX stock?
The current stock price of YMTX is 1.89 USD. The price increased by 8.62% in the last trading session.
What is the dividend status of YUMANITY THERAPEUTICS INC?
YMTX does not pay a dividend.
What is the ChartMill rating of YUMANITY THERAPEUTICS INC stock?
YMTX has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the GICS sector and industry of YMTX stock?
YUMANITY THERAPEUTICS INC (YMTX) operates in the Health Care sector and the Biotechnology industry.
Can you provide the PE ratio for YMTX stock?
YUMANITY THERAPEUTICS INC (YMTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.64).